7107 related articles for article (PubMed ID: 2751735)
1. Antitumor activity of an ionic titanocene tetrachloroferrate derivative against some solid experimental tumors.
Köpf-Maier P; Klapötke T
Arzneimittelforschung; 1989 Apr; 39(4):488-90. PubMed ID: 2751735
[TBL] [Abstract][Full Text] [Related]
2. Tumor inhibition by ferricenium complexes. Activity against some solid experimental tumors.
Köpf-Maier P; Klapötke T
Arzneimittelforschung; 1989 Mar; 39(3):369-71. PubMed ID: 2757661
[TBL] [Abstract][Full Text] [Related]
3. Ionic titanocene complexes: a new type of antitumor agent.
Köpf-Maier P; Neuse E; Klapötke T; Köpf H
Cancer Chemother Pharmacol; 1989; 24(1):23-7. PubMed ID: 2720888
[TBL] [Abstract][Full Text] [Related]
4. Tumor inhibition by titanocene complexes. Activity against B16 melanoma and colon 38 carcinoma.
Köpf-Maier P; Köpf H
Arzneimittelforschung; 1987 May; 37(5):532-4. PubMed ID: 3619974
[TBL] [Abstract][Full Text] [Related]
5. Antitumor metallocenes: new developments and toxicologic features.
Köpf-Maier P; Köpf H
Anticancer Res; 1986; 6(2):227-33. PubMed ID: 3707060
[TBL] [Abstract][Full Text] [Related]
6. Antineoplastic activity of azacarbazoles. II. Effect of alpha-carboline and its derivatives on transplantable animal neoplasms.
Fiszer-Maliszewska L; Mordarski M
Arch Immunol Ther Exp (Warsz); 1987; 35(2):221-4. PubMed ID: 3447536
[TBL] [Abstract][Full Text] [Related]
7. Tumor inhibition by titanocene complexes: activity against sarcoma 180.
Köpf-Maier P; Preiss F; Marx T; Klapötke T; Köpf H
Anticancer Res; 1986; 6(1):33-7. PubMed ID: 3954328
[TBL] [Abstract][Full Text] [Related]
8. Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour.
Valadares MC; Ramos AL; Rehmann FJ; Sweeney NJ; Strohfeldt K; Tacke M; Queiroz ML
Eur J Pharmacol; 2006 Mar; 534(1-3):264-70. PubMed ID: 16513106
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of dichlorobis(1-phenylbutane-1,3-dionato)titanium (IV) and budotitane. Two representatives of the new class of antitumor-active bis-beta-diketonato metal complexes.
Keppler BK; Schmähl D
Arzneimittelforschung; 1986 Dec; 36(12):1822-8. PubMed ID: 3566844
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of titanocene dichloride in xenografted human renal-cell carcinoma.
Köpf-Maier P
Anticancer Res; 1999; 19(1A):493-504. PubMed ID: 10226588
[TBL] [Abstract][Full Text] [Related]
11. Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors.
Guilbaud N; Kraus-Berthier L; Meyer-Losic F; Malivet V; Chacun C; Jan M; Tillequin F; Michel S; Koch M; Pfeiffer B; Atassi G; Hickman J; Pierré A
Clin Cancer Res; 2001 Aug; 7(8):2573-80. PubMed ID: 11489841
[TBL] [Abstract][Full Text] [Related]
12. Markedly improved efficacy of edatrexate compared to methotrexate in a high-dose regimen with leucovorin rescue against metastatic murine solid tumors.
Sirotnak FM; Otter GM; Schmid FA
Cancer Res; 1993 Feb; 53(3):587-91. PubMed ID: 8425192
[TBL] [Abstract][Full Text] [Related]
13. Antineoplastic effect of orally administered 1-alkyl carbamoyl derivatives of 5-fluorouracil on sc implanted Lewis lung carcinoma and B16 melanoma.
Iigo M; Hoshi A; Nakamura A; Kuretani K
Cancer Treat Rep; 1979; 63(11-12):1895-9. PubMed ID: 118802
[TBL] [Abstract][Full Text] [Related]
14. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines.
Tsuruo T; Yusa K; Sudo Y; Takamori R; Sugimoto Y
Cancer Res; 1989 Oct; 49(20):5537-42. PubMed ID: 2790778
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer.
Utsugi T; Shibata J; Sugimoto Y; Aoyagi K; Wierzba K; Kobunai T; Terada T; Oh-hara T; Tsuruo T; Yamada Y
Cancer Res; 1996 Jun; 56(12):2809-14. PubMed ID: 8665518
[TBL] [Abstract][Full Text] [Related]
16. Activity of a novel 4-quinolinecarboxylic acid, NSC 368390 [6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarb oxylic acid sodium salt], against experimental tumors.
Dexter DL; Hesson DP; Ardecky RJ; Rao GV; Tippett DL; Dusak BA; Paull KD; Plowman J; DeLarco BM; Narayanan VL
Cancer Res; 1985 Nov; 45(11 Pt 1):5563-8. PubMed ID: 4053030
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of phenyl substituted dihalogenobis (1-phenyl-1,3-butanedionato)titanium (IV) compounds.
Keppler BK; Diez A; Seifried V
Arzneimittelforschung; 1985; 35(12):1832-6. PubMed ID: 4096739
[TBL] [Abstract][Full Text] [Related]
18. 4'-O-tetrahydropyranyladriamycin as a potential new antitumor agent.
Tsuruo T; Iida H; Tsukagoshi S; Sakurai Y
Cancer Res; 1982 Apr; 42(4):1462-7. PubMed ID: 7060020
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity and hematotoxicity of a new, substituted dihydrobenzoxazine, FK973, in mice.
Shimomura K; Manda T; Mukumoto S; Masuda K; Nakamura T; Mizota T; Matsumoto S; Nishigaki F; Oku T; Mori J
Cancer Res; 1988 Mar; 48(5):1166-72. PubMed ID: 3342397
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect of N alpha-benzyloxycarbonyl-N,N-bis-(2-halogenethyl)-hydrazide derivatives of amino acids.
Karaivanova MH; Zakhariev SG; Golovinsky EV
Neoplasma; 1980; 27(2):137-42. PubMed ID: 7393353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
